• Kyra O'Brien, Cameron Coykendall, Melanie Kleid, Kristin Harkins, Nathaniel Chin, Justin T Clapp, and Jason Karlawish.
• University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. kyra.o'brien@pennmedicine.upenn.edu.
• J Gen Intern Med. 2024 Jul 1; 39 (9): 171317201713-1720.

BackgroundThe efficiencies of plasma Alzheimer's disease (AD) biomarkers could facilitate early AD diagnosis. Unfortunately, limited knowledge exists about whether and how they would be used by clinicians.ObjectiveTo identify and compare determinants of plasma AD biomarker use reported by primary care providers and dementia specialists.DesignSemi-structured interviews with clinicians organized using Rogers' Diffusion of Innovations theory and analyzed using an iterative coding approach.ParticipantsThe subjects were internal and family medicine, neurology, and geriatrics providers with varying degrees of expertise in dementia diagnosis and care.Main MeasuresFactors influencing a clinician's decision to use or not use plasma AD biomarkers in clinical practice.Key ResultsWe interviewed 30 clinicians (16 family or internal medicine providers, 8 geriatricians, and 6 neurologists). Fifteen were dementia specialists. Hesitance to use plasma AD biomarkers was due to perceived lack of effective treatments for AD, limited access to supports, and stigma. Plasma AD biomarkers would be more readily adopted by clinicians with dementia expertise.ConclusionsSeveral factors will influence clinical use of plasma AD biomarkers. Some of them may inform the design of interventions to promote the effective and appropriate clinical translation of these tests.© 2023. The Author(s), under exclusive licence to Society of General Internal Medicine.

19 keywords...

hide…